Lu-177-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results 177Lu-3BP-227 for neurotensin receptor 1-targeted therapy of metastatic pancreatic adenocarcinoma: first clinical results. J Nucl Med. 2018;59:809-814... RP Baum,A Singh,C ...
177Lu-3BP-227 for neurotensin receptor 1-targeted therapy of metastatic pancreatic adenocarcinoma--First clinical results. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2017. [CrossRef]
2021;110(1):227–36. https://doi.org/10.1016/j.ijrobp.2020.08.014. Article PubMed Google Scholar Sminia P, Schneider CJ, Koedooder K, van Tienhoven G, Blank LE, González DG. Pulse frequency in pulsed brachytherapy based on tissue repair kinetics. Int J Radiat Oncol Biol Phys. 1998...
Mol Pharm. 2014;11(3):800–7. https://doi.org/10.1 021/mp4005047. Macklis RM. How and why does radioimmunotherapy work? Int J Radiat Oncol Biol Phys. 2004;59(5):1269–71. https://doi.org/1 0.1016/j.ijrobp.2004.04.008. Majkowska A, Bilewicz A. Formation kinetics and stability...
227wz,com_www227wzcom,akak88,www,45nnn,com,loewe,www,182abc,com,www,hbjuxinnet,www,111gx,com_www111gxcom,qylbbs8,com_qylbbs8com,www,2222lang3,com_www2222lang3com,abab,456,com,17gaoab,co,63caoab,com,wwwht345hhcyz:9527,伊甸园,silingge,huynh,dong_huynhdong,欧美在线观看网址综合,www...
177Lu-IPN01087 (also called 177Lu-3BP-227) is a DOTA (tetraxetan)-conjugated NTSR1 antagonist that has demonstrated anti-tumor activity in vitro and in vivo. This study (NCT03525392; EudraCT: 2017-001263-20) will evaluate 177Lu-IPN01087 safety and efficacy, including objective response rate...
In the 177Lu ligand competitive binding assay, FL-091 and 3BP-227 displayed IC50 of 0.21 and 4.46 nM, respectively. The IC50 values for FL-091 and 3BP-227 in FLIPR antagonist assay were 11.70 and 45.41 nM, respectively. High and sustained tumor uptake was observed for 177Lu-FL-091 in...
First dosimetric results with Lu-177 3BP-227 in a patient with pancreatic cancer Current preclinical dosimetric models often fail t C Schuchardt,H Kulkarni,C Smerling,... 被引量: 3发表: 2014年 Dosimetric Analysis of a Phase I Study of PSMA-Targeting Radiopharmaceutical Therapy With [177Lu]Lud...
Haase, CReineke, USchuchardt C, Kulkarni HR, Smerling C, Osterkamp F, Haase C, Reineke U, et al. First dosimetric results with Lu-177 3BP-227 in a patient with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2014;41:S332. PW049....